A citation-based method for searching scientific literature

Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
Times Cited: 38



James Mu, John Woods, Yun-Ping Zhou, Ranabir Sinha Roy, Zhihua Li, Emanuel Zycband, Yue Feng, Lan Zhu, Cai Li, Andrew D Howard, David E Moller, Nancy A Thornberry, Bei B Zhang. Diabetes 2006
Times Cited: 355




List of shared articles



Times cited

Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.
Bárbara Torrecillas-Baena, María Ángeles Gálvez-Moreno, José Manuel Quesada-Gómez, Gabriel Dorado, Antonio Casado-Díaz. Stem Cell Rev Rep 2021
0

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
74

The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes.
Yunjuan Zhao, Lin Yang, Xiangbing Wang, Zhiguang Zhou. Diabetes Metab Res Rev 2014
39

Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.
Xia Wang, Peilin Zheng, Gan Huang, Lin Yang, Zhiguang Zhou. Clin Exp Med 2018
17

Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice.
Yanqing Zhang, Genevieve E Fava, Meifen Wu, Wynn Htun, Thomas Klein, Vivian A Fonseca, Hongju Wu. J Endocr Soc 2017
1

Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Susana Nogueira Diniz, Andrea Fabbri, Marco Infante. Int Immunopharmacol 2021
1